Background: Transglutaminase 3 (TG3) belongs to a family of Ca 2+dependent enzymes which catalyse protein crosslinking. TG3 is important for proper development of the skin and hair shaft, and knockout mice for the Tgm3 gene are sensitive to UVB-induced photodamage due to aberrations in cornified envelope formation. Loss of TG3 is reported in head and neck and oesophageal squamous cell carcinoma, yet, its expression in skin cancer has not been studied. Objectives: The aim of the present study was to analyse the expression pattern of TG3 in skin cancer. Materials and methods: TG3 expression was investigated based on immunohistochemical staining of a tissue micro-array of different types of skin cancer, as well as meta-analysis of public gene array data. Results: Our findings demonstrated that TG3 is normally expressed in spinous/granular layers of the epidermis, but is absent in melanocytes as well as melanoma samples. As expected, its expression was absent in poorly differentiated squamous cell carcinoma of the skin. Surprisingly, we show that samples of basal cell carcinoma demonstrated strong staining for TG3 both in the cytoplasm and nucleus. Furthermore, at the mRNA level, the expression pattern of TGM3 was crucially altered in BCC, but not other types of skin cancer. Conclusion: These findings lead to new questions regarding TG3 involvement in basal cell carcinoma tumourigenesis. Moreover, the expression pattern of TG3 renders it a potential specific marker for basal cell carcinoma diagnosis.
T he family of transglutaminases (TGs) is composed of Ca 2+ -dependent enzymes whose main function is to catalyse protein crosslinking [1] . Transglutaminase 3 (TG3) is expressed in the differentiated layer of the epidermis and hair follicle. During keratinocyte differentiation, similar to the other TG members, TG1 and TG5, [2] [3] [4] , proteolysis is required for TG3 activation [5] . It was demonstrated that Sp1 and ETS transcription factors promote TG3 gene (TGM3) expression in squamous epithelia [6] , moreover, two different transcription variants of TGM3 were identified [7] . The main protein substrates for TG3 and TG1 are loricrin, involucrin, and the family of small proline-rich proteins (SPRs). Crosslinking between loricrin and SPRs contributes to the cornification of the skin [3] . Even though Tgm3 -/mice do not show any strong abnormalities in skin formation, a more invasive percutaneous penetration of fluorescein isothiocyanate (FITC) in KO mice was observed [8] . Recently, our laboratory demonstrated that the absence of Tg3 sensitizes the skin to damage induced by UVB irradiation [9] . Moreover, a mutation within the TGM3 gene was shown to be one of the causes of uncombable hair syndrome [10] . Multiple studies have demonstrated the downregulation of TG3 both at the RNA and protein level in head and neck squamous cell carcinomas [11] [12] [13] [14] [15] [16] [17] . As a molecular mecha-nism of TG3 repression, hypermethylation of CpG islands within the TGM3 promoter has been proposed [18] . Furthermore, TGM3 was shown as a putative tumour-suppressor gene in oesophageal cancer, in which its expression was downregulated and associated with tumour proliferation and migration [19, 20] . Skin cancer is the most common type of cancer. There are three different major types of skin cancer: basal cell carcinoma, squamous cell carcinoma (referred to as nonmelanoma skin cancer), and malignant melanoma. Basal cell carcinoma is the most common type of cancer in the world. It preferentially arises from stem cells of the hair follicle [21] , meanwhile squamous cell carcinoma arises from epidermal keratinocytes and can be more aggressive and lead to metastasis [22] . Melanoma arises from melanocytes and its incidence is minor relative to non-melanoma skin cancers, however, it is the deadliest form of skin cancer [23] . Recently, a single nucleotide polymorphism was found within the TGM3 gene, associated with a higher risk of basal cell carcinoma incidence among Icelanders [24] . However, the expression of TG3 in skin cancers has not yet been investigated. Here, using a tissue micro-array (TMA) approach combined with meta-analysis of skin cancer data sets, we investigated TG3 expression in different patients. We observed TG3 down-regulation in melanoma and aggressive squamous cell carcinomas, but a high level of expression in basal cell carcinoma, making TG3 a suitable biomarker for this type of skin cancer.
Materials and methods

Immunohistochemical staining
A skin cancer tissue micro-array, containing 10 samples of normal skin, 10 samples of malignant melanoma, 39 samples of cutaneous squamous cell carcinoma, and 13 samples of cutaneous basal cell carcinoma, was purchased from US Biomax (Cat. No. SK801c, Rockville, MD, USA). Other samples of cBCC from this study were utilized with the approval (Protocol No. 130/18) of the institutional review board of the University Hospital "Policlinico Tor Vergata" (Rome, Italy) and prior patient consent. The immunohistochemical staining for Ki67 and Ep-CAM were performed using anti-Ki67 antibody (Cat. No. 790-4286, Ventana, Oro Valley, AZ, USA) and anti-Ep-CAM antibody (Cat. No. 760-4383, Ventana), following the manufacturer's indications using the automatised BenchMark ULTRA slide staining system (Ventana). For TG3 staining, sections were dewaxed and rehydrated, incubated for blocking of endogenous peroxidases in 0.03% solution of hydrogen peroxide in methanol, and antigen retrieval was then performed by boiling the sample in the 0.01 M citrate buffer pH 6.0 for 10 minutes in a microwave. Slides were incubated with anti-TG3 antibody (1:300; Cat. No. C2D, Covalab, Villeurbanne, France) for 20 minutes at room temperature. The signal was detected using UltraTek HRP anti-polivalent DAB staining system (ScyTek, Logan, UT, USA) and the slides were then counterstained with haematoxylin, dehydrated, and mounted. Slides were scanned using a Ventana iCoreo scanner (Ventana) with 40x objective. Images of haematoxylin/eosin staining for TMA were downloaded from the manufacturer's website (www.biomax.us).
Immunofluorescence and confocal microscopy
Paraffin-embedded sections of BCC were dewaxed and rehydrated, and antigen retrieval was then performed by boiling the sample in 0.01 M citrate buffer pH 6.0 for 10 minutes in a microwave. To reduce tissue autofluorescence, samples were incubated for 45 minutes in 0.1 M sodium tetrahydroborate solution, followed by one hour of blocking with 5% goat serum in PBS. Slides were incubated with anti-TG3 antibody (1:300) and anti-Loricrin (1:300; Poly19051, BioLegend, San Diego, CA, USA) overnight at 4 • C. Then, sections were incubated for one hour at room temperature with secondary anti-mouse and anti-rabbit 488-or 568-AlexaFluor conjugated antibodies (1:1,000; Invitrogen, Carlsbad, CA, USA) together with 1 g/mL DAPI (Sigma, St. Louis, MO, USA) for nuclear DNA staining. Sections were analysed with a confocal laser microscope (NIKON Eclipse Ti) using NIS-Elements AR Ver. 4.4 software (Nikon, Tokyo, Japan).
Histological scoring of the samples
Samples were scored in a blinded manner by a pathologist using a semi-quantitative method. Cases were analysed for staining intensity, which was scored as 0 (not detected), 1+ (weak), 2+ (intermediate), and 3+ (strong). For each case, the histological "H-score" (0-300) was calculated by multiplying the percentage of positive cells (0%-100%) by the intensity (0-3). Percentage of Ki67 positive samples was calculated as the number of Ki67 positive neoplastic cells per total number of neoplastic cells x 100%. Ten random fields were analysed for each sample.
Bioinformatic analysis
Normalized values for TGM1, TGM3, TGM5, LOR, and IVL expression in the skin cancer samples were obtained from NCBI GEO portal (accession number: GSE7553 [25] ). Analysis of co-expression was performed using the publicly available on-line platform "R2: Genomics Analysis and Visualization Platform" (r2.amc.nl). Gene ontology analysis was carried out using the DAVID on-line platform (david.ncifcrf.gov).
Statistical analysis
All statistical analyses were performed using GraphPad Prism 7.0 software (San Diego, CA, USA). For the analysis of gene array data and TG3 protein level from the tissue micro-array experiment, the significance level (p) was calculated using Welch's unequal variances t-test. Values of p < 0.05 were considered significant. Violin plots were generated in R using ggplot2 package.
Results
TG3 is differentially expressed in skin cancer
Previously published data revealed an important role of TG3 in oesophageal and head and neck cancer [14, 19] , meanwhile its expression pattern in skin cancer remains unveiled. To analyse the expression of TG3 at the protein level, we used a tissue micro-array containing normal skin, cutaneous melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). Firstly, we performed immunohistochemical staining of TG3 using 10 samples of normal human skin ( figure 1A) . We observed a homogeneous distribution of the staining among all specimens regardless of the patients' age, sex, or biopsy anatomical site (supplementary table 1). In line with previous studies [26] , all samples showed localisation of TG3 in the upper spinous and granular layers, meanwhile basal and cornified layers, as well as the dermis, were negative for TG3. As a marker of proliferation, we used Ki67. We then analysed the expression of TG3 in tumour samples; almost all samples of melanoma were negative for TG3 staining (figure 1B, supplementary table 2). Based on analysis of TG3 expression in the SCC samples ( figure 1C, supplementary table 3 ), the majority of samples (24/39) were negative for TG3. Several samples of low-grade and well-differentiated tumours showed positive staining only in the differentiated cells relative to the poorly-differentiated samples. Surprisingly, we found a very heterogenous distribution of TG3 expression in the BCC samples ( figure 1D, supplementary table 4) ; several samples were negative (4/13) or weakly-stained (4/13) for TG3, and almost half showed a very strong staining (5/13). However, more precise analysis of the samples in a blinded manner by three independent pathologists (University Hospital "Policlinico Tor Vergata", Rome, Italy) did not result in definitive conclusions regarding the diagnosis of TG3-negative samples. To resolve this problem, we performed immunohistochemical staining for Ep-CAM, which was shown to be a specific marker for basal cell carcinoma of the skin [27] . Surprisingly, only some samples (4/13) were positive (H-score > 100) for this protein (supplementary table 4 ). Hence, we decided to perform additional staining for six BCC sections from the Pathology unit of "Policlinico Tor Vergata" Hospital (Rome, Italy). We found all samples to be strongly positive for both Ep-CAM and TG3 ( figure 2A) . Interestingly, in TG3-positive samples, localisation was not only cytoplasmic but also nuclear. Further statistical analysis of TG3 expression based on the skin cancer tissue micro-array and additional cases ( figure 2B, C) revealed a strong decrease in TG3 level in melanoma (p = 5.3 × 10 −6 ) and SCC (p = 5.9 × 10 −6 ) samples relative to the normal epidermis. On the other hand, the TG3 level in the BCC samples (only Ep-CAMpositive samples from TMA and additional cases) was significantly increased relative to the normal epidermis (FC = 2.2; p = 6.5 × 10 −5 ).
Differentiation-related profile of TGM3 expression is lost in BCC, but not in SCC
For further confirmation of our observations, we analysed the expression of TGM3 at the mRNA level in normal skin and skin cancers from a publicly available gene array (accession number: GSE7553, [25] ( figure 3A) . We observed that TGM3 expression is significantly decreased in melanoma samples (p = 0.026), meanwhile there were no significant changes in TGM3 expression in SCC (p = 0.557).
In line with our results, we observed a significant two-fold increase in TGM3 level in basal cell carcinoma samples (p = 0.011). Hence, we decided to investigate whether the expression of other skin-related TGs (such as TGM1 and TGM5) or their common substrates (such as LOR and IVL) was altered in BCC relative to normal skin. Our results showed no significant changes in the expression of any of the genes analysed (p > 0.15), indicating that increased expression of TG3 in BCC is specific and not linked to a de-regulation of the differentiation process ( figure 3B ). To confirm these data at the tissue level, BCC samples were costained for TG3 and its substrate, loricrin. As highlighted in figure 3C , TG3 and loricrin were partly co-expressed in the upper layers of the skin adjacent to the tumour, meanwhile the tumour regions were positive for TG3 and completely negative for loricrin. To support the observation that TG3 is uniquely overexpressed in BCC, irrespective of other differentiation-related genes, we performed correlation analysis of expression of TGM1, TGM3, TGM5, LOR, and IVL in normal skin and skin cancer using the data from the gene array (GSE7553). As expected, we observed a high correlation (R > + 0.75) between the expression of all genes analysed in normal skin, melanoma, and SCC samples ( figure 4A) . Surprisingly, in BCC samples, we found that this trend was maintained only between TGM1, TGM5, LOR, and IVL (R > + 0.75), but not TGM3 (R≈ 0). The gene ontology analysis ( figure 4B ) revealed that the top 300 genes co-expressed with the TG substrate, LOR, are strongly related to an epidermal differentiation cluster in all types of skin cancer (p: 10 −4 ÷10 −50 ). Interestingly, this trend can be noticed also for TGM3 but only in melanoma and SCC samples (p: 10 −2 ÷10 −50 ), while the differentiationrelated pattern of TGM3 expression is completely lost in BCC samples (GO groups: "aromatic/nitrogen/lipid compound biosynthesis", "water-soluble vitamin metabolism", etc.; p > 10 −3 ). These data indicate that, unlike other skin cancers, in BCC, despite the strong de-regulation of TG3 expression, other proteins related to keratinization are not altered.
Discussion
Skin differentiation is a specialized form of cell death, but unlike apoptosis, p53, Bcl2 [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] and other classic proapoptotic effectors are not involved, whereas TG enzymes (TG1, TG3, and TG5) play a crucial role [2, [4] [5] [6] 39] . TG3 is a Ca 2+ -dependent enzyme, important for protein crosslinking. It is mainly expressed in squamous epithelia such as the epidermis, as well as in hair follicles. Its crosslink-ing activity contributes to the formation of the cornified cell envelope and hair shaft [3] . Interestingly, the skin of Tgm3 -/mice shows higher permeability and is more sensitized to photodamage induced by UVB-irradiation [8, 9] . Moreover, loss of TG3 was described in head and neck and oesophageal squamous cell carcinoma [18, 19] , indicating its possible involvement in epithelial cancers. However, the role of TG3 in skin cancer remains unresolved, thus we investigated its expression with regards to this pathology. Firstly, we performed immunohistochemical staining using a tissue micro-array, containing different types of skin cancer as well as normal skin controls. We observed positive staining for TG3 in the upper spinous and granular layers of normal epidermis, while basal layer cells as well as melanocytes were negative. Indeed, melanoma samples maintained negative staining for TG3 as expected due to the non-squamous origin of this type of skin cancer. Interestingly, most squamous cell carcinoma samples were negative for TG3 as well. The latter confirms previously published data [18, 19] . Of note, SCCs that stained positively for TG3 were well differentiated around keratin pearls. Conversely, we found a very strong signal for TG3 in basal cell carcinoma samples. Surprisingly, in these samples, TG3 was detected both in the cytoplasm and nucleus. Since BCC carcinogenesis shares several common features Further investigation of TGM3 expression at the mRNA level in skin cancer revealed a dramatic de-regulation of its differentiation-related pattern of expression only in BCC samples, and not in SCC or melanoma. Interestingly, the expression of other related genes, such as TGM1, TGM5, LOR, or IVL, strongly correlated with differentiation in all samples, hence de-regulation of TGM3 expression cannot be explained by aberrations in the differentiation programme, but implies the existence of additional transcriptional activities which trigger TGM3 expression exclusively during BCC tumourigenesis. More accurate analysis reveals that the cells of the basal layer of normal skin, where BCC originates from, are negative for TG3, in contrast to tumour cells. This observation indicates that during initiation of BCC, several pathways lead to transcriptional activation of TGM3 expression. BCCs are characterised by the altered Hedgehog pathway and, as a consequence, abnormal activity of GLI transcription factors [40] . Of interest, several binding sites for GLI2 were identified within the promoter region of TGM3 [41, 42] . Hence, a possible scenario of abnormal TG3 expression in BCC could be related to transcriptional activation of TGM3 by GLI2. However, the exact mechanisms for TG3 regulation remain completely elusive. Of note, the pattern of TG3 expression is similar to that of Ep-CAM, specifically found in this type of skin cancer. In fact, routinely, BCC diagnosis is also confirmed by positive Ep-CAM staining [43] . Ep-CAM is absent in normal skin, and negative staining for Ep-CAM in tissue could be due to inappropriate fixation or processing of the samples, which may lead to uncertain conclusions regarding the diagnosis. As TG3 is expressed in both BCC cells and the granular layer of normal epidermis, TG3 staining of adjacent skin may serve as an internal positive control for antibody and sample preparation, rendering TG3 a potentially more accurate diagnostic marker for BCC relative to Ep-CAM. Altogether, our findings demonstrate an abnormal overexpression of TG3 in basal cell carcinoma. Further research is necessary to support these observations with a greater number of samples, to reveal molecular mechanisms responsible for this phenomenon. The data presented indicate TG3 as a new potential specific marker for the diagnosis of cutaneous basal cell carcinoma.
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